| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-944 | |
| Phytochemical name or plant extracts | Taiwanin E | |
| PMID | 25918798 | |
| Literature evidence | Taiwanin E presented a potent anti-proliferation activity on the growth of a human breast adenocarcinoma cell line (MCF-7), with an IC50 value for cytotoxicity of 1.47 μM. | |
| IUPAC name | 9-(1,3-benzodioxol-5-yl)-5-hydroxy-6H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one | |
| Phytochemicals’ class or type of plant extracts | Lignan | |
| Source of phytochemicals or plant Extracts | Eleutherococcus trifoliatus | |
| Geographical availability | Assam, China South-Central, China Southeast, Myanmar, Nepal, Philippines, Taiwan, Thailand, Vietnam | |
| Plant parts | branches | |
| Other cancers | Breast cancer | |
| Target gene or protein | pRb, CDK4, p21, p27, CDK6, Cyclin D3, Cyclin D4 | |
| Gene or Protein evidence | After treatment with taiwanin E, phosphorylation of retinoblastoma protein (pRb) in MCF-7 cells was inhibited, accompanied by a decrease in the levels of cyclin D1, cyclin D3 and cyclin-dependent kinase 4 (cdk4) and cdk6, in addition, there was an increase in the expression of cyclin-dependent kinase inhibitors p21(WAF-1/Cip) and p27(Kip1). | |
| Target pathways | NA | |
| IC50 | 1.47 μM against MCF-7 | |
| Potency | The results suggest that taiwanin E inhibits cell cycle progression of MCF-7 at the G0/G1 transition. | |
| Cell line/ mice model | MCF-7 | |
| Additional information | Collectively, the present study highlights the prospective therapeutic efficacy of Taiwanin E against arecoline and 4-nitroquinoline-1-oxide-induced oral cancer. | |
| PubChem ID | 493164 | |
| Additional PMIDs | 31921618 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:90440-1 | |
| Safety | NA |